Soluble membrane attack complex in the blood and cerebrospinal fluid of HIV-infected individuals, relationship to HIV RNA, and comparison with HIV negatives

J Neuroimmunol. 2017 Oct 15;311:35-39. doi: 10.1016/j.jneuroim.2017.07.014. Epub 2017 Jul 23.


The soluble membrane attack complex (sMAC) represents the terminal product of the complement cascade. We enrolled 47 HIV+ adults (12 of whom underwent a second visit at least 24weeks after starting therapy) as well as 11 HIV negative controls. At baseline, cerebrospinal fluid (CSF) sMAC was detectable in 27.7% of HIV+ individuals. CSF sMAC correlated with CSF HIV RNA levels and was more likely to be detectable in HIV+ individuals on cART compared to HIV negative controls. In HIV+ participants, there were negative association trends between sMAC and neurocognitive performance but these did not reach statistical significance.

Keywords: Acquired immunodeficiency syndrome; Complement; Human immunodeficiency virus; Membrane attack complex; Neurocognitive disorder.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Retroviral Agents / therapeutic use
  • CD4-Positive T-Lymphocytes / pathology
  • CD4-Positive T-Lymphocytes / virology
  • Cognition Disorders / etiology
  • Cognition Disorders / virology
  • Complement Membrane Attack Complex / metabolism*
  • Female
  • HIV Infections / blood*
  • HIV Infections / cerebrospinal fluid*
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • HIV-1 / genetics*
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • RNA / cerebrospinal fluid*
  • Statistics as Topic


  • Anti-Retroviral Agents
  • Complement Membrane Attack Complex
  • RNA